ClinicalTrials.gg
RecruitingNCT04479072Updated May 4, 2026

Aspirin and Preeclampsia

A Phase 4 interventional study of Aspirin 81 mg and Placebo in Preeclampsia Postpartum, sponsored by University of Chicago. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by University of Chicago · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 52 studies testing aspirin in Pre-Eclampsia — 18 open to participants now, 22 under way, 5 of them phase 3. Aspirin · Pre-Eclampsia.

Planned enrollment
31st of 52
180 · median 235
Started
2021
with 5 others
Phase 4
16 of 52
5 open now
Primary completion
2026-12
later than 9 of 21 live
Registered
23rd of 52
by date

Among the 52 studies testing aspirin in Pre-Eclampsia, this one is the 31st largest by planned enrollment, is one of 6 that started in 2021, is one of 16 in phase 4, reaches primary completion later than 9 of the 21 other live ones, and was the 23rd registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

18 of the 52 studies testing aspirin in Pre-Eclampsia are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing aspirin in Pre-Eclampsia, or all of them as a file.
02

Study summary

This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.

Read the detailed description

The primary objective of the main part of this trial is to mechanistically compare the effect of postpartum aspirin therapy versus placebo in preeclamptic patients identified as high risk for postpartum cardiac dysfunction using Activin A. The intent is to evaluate the effect of selective treatment based on Activin A status rather than treatment for all postpartum preeclamptic women.

After informed consent, 5cc of blood will be collected from the median cubital vein on antepartum admission to labor and delivery for Activin A screening. The patient will be subjected to a total of 2 such blood draws- a single draw at screening, one at their 6 month postpartum visit. The member of the study team carrying out the blood draw will immediately label the specimen in the presence of the subject, after the collection and before leaving the patient's bedside, room, cubicle or surgical suite. The guidelines from, "The University of Chicago Medicine Policy and Procedure Manual - Phlebotomy Service Infection Control 04-26" will be followed for specimen collection and transport. Activin A levels based on our previous data will be classified as elevated if greater than 23.74 ng/ml in the last trimester of pregnancy (4). This threshold was selected on the basis of our prior data suggesting an inflection point in the rate of abnormal GLS postpartum at this concentration. Patients with elevated Activin A levels will be randomized to a placebo group receiving routine postpartum cardiovascular standard of care or to an intervention arm with 81 mg daily aspirin therapy added to care at their postpartum delivery stay. The rationale for only randomizing women with elevated Activin A levels is that among women with an elevated Activin A antepartum, 85% developed abnormalities in GLS at one year postpartum versus 25% in women with non-elevated Activin A levels. Women whose Activin A levels are not elevated will receive the same care as that provided to the placebo group and will also be followed for one year (n=60). All other subjects who meet the criterial of elevated Activin A levels, will either be randomized to the aspirin therapy group (N = 60) or a placebo group (N = 60). The investigators choose postpartum Aspirin therapy post-delivery to avoid any immediate delivery or C-section associated bleeding complications and to coincide with their postpartum well-baby visit.

The investigator will determine the blood Activin A levels at 6 months after delivery, measured using ELISA. The samples will be assayed for Activin A level using commercially available ELISA kits (Ansh Labs; Webster, TX) following the manufacturer's recommendations. Each sample will be run in triplicate and the values averaged. GLS at 6 months after delivery will be measured using fully automated vendor-independent software that uses a computer learning algorithm to facilitate endocardial border detection.

Mean arterial pressure, and other indices of systolic and diastolic function (ejection fraction (EF), early filling/atrial contraction (E/A), deceleration time (DT), mitral annular motion (E'), and left atrial volume index) measured at the baseline and 6 months postpartum. Transthoracic echocardiograms will be performed and reported according to American Society of Echocardiography guidelines. Ejection fraction and left atrial volume will be calculated using the Simpson's biplane disc method. Left ventricular mass index (LVMI) will be calculated using the area length method.

03

Conditions studied

  • Preeclampsia Postpartum

Keywords

  • Preeclampsia
  • Postpartum GLS Levels
  • Postpartum Activin A Levels
  • Aspirin
  • Cardiac Postpartum Therapy
  • Hypertension
  • Cardiovascular disease
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pregnant Adults between 18 and 45 years of age
  2. Diagnosed with preeclampsia
  3. Presenting for delivery with a singleton gestation.

Exclusion criteria

Exclusion Criteria:

  1. We will exclude patients in labor
  2. Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation
  3. Plan to deliver outside of the participating site
  4. Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI.
  5. Aspirin allergy
  6. Clear indication for aspirin therapy or to aspirin therapy
  7. conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders)
  8. Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study.
  9. Those who cannot provide consent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    Intervention Arm

    60 subjects will be randomly assigned to this arm. The subjects in this arm will receive a daily dose of aspirin 81 mg.

    Drug: Aspirin 81 mg

  • Placebo comparator
    Placebo Arm

    60 subjects will be randomly assigned to this arm. The subjects in this arm will receive a daily dose of a placebo pill

    Drug: Placebo

  • No intervention
    Observational Arm

    60 subjects will be placed in the observational arm. These subjects will not receive any intervention but will be followed and asked to return at the same time interval as the other 2 groups.

Interventions

  • DrugAspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.

    Also known as: acetylsalicylic acid 81 mg

  • DrugPlacebo

    Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.

06

What researchers measure

Primary outcomes

  1. Difference in Activin A levels

    The primary outcome will compare Activin A levels at 6 months between patients randomized to aspirin therapy versus placebo and the observational group.

    Time frame: 6 Months

  2. GLS percentages

    The primary outcome will compare GLS levels as a percentage (%) at 6 months between patients randomized to aspirin therapy versus placebo and the observational group.

    Time frame: 6 months

Secondary outcomes

  1. Mean Arterial Pressure

    Difference in mean arterial pressure in subjects, from their baseline to 6 month TTE

    Time frame: 6 Months

  2. Ejection Fraction %

    Comparing the difference in the ejection fraction percentages, from the subjects baseline to 6 month TEE.

    Time frame: 6 Months

  3. Deceleration Time

    Comparing the difference between deceleration time from subjects from their baseline to 6 month TTE.

    Time frame: 6 Months

  4. Mitral Annular Motion

    Comparing the difference between mitral annular motion, in millimeters (mm), from subjects baseline to 6 month TTE.

    Time frame: 6 Months

  5. Left Atrial Volume Index

    Comparing the difference between left atrial volume index, from the subjects baseline to 6 month TTE.

    Time frame: 6 Months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Dec 2026, 69 months after the start.

Of 35 phase 4 interventional studies under Pre-Eclampsia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 35. This study's planned 69 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2020
First posted
Jul 21, 2020
StartActual
Feb 15, 2021
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 31, 2026
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04479072
Responsible party
Sponsor
First posted
Jul 21, 2020
Start date
Feb 15, 2021
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 4, 2026

Study contacts

Sajid Shahul, MD, PhD
Contact
sshahul1@dacc.uchicago.edu
773-398-2956
Colleen Duncan, RN
Contact
cduncan@bsd.uchicago.edu
7738342892

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion